Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Subscribe To Our Newsletter & Stay Updated
